Thyroid Cancer Drugs Market Report 2026

Thyroid Cancer Drugs Market Overview

• Thyroid Cancer Drugs market size has reached to $1.32 billion in 2025 • Expected to grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Surge In Incidences Of Thyroid Cancer Driving Market Growth Due To Rising Diagnosis Rates Leading To Greater Demand For Effective Therapies • Market Trend: Advancements In Thyroid Cancer Treatment With Selpercatinib Approval • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Thyroid Cancer Drugs Market?

The thyroid cancer drugs refer to drugs that are used to treat thyroid cancer by blocking several different kinase proteins. These medications function primarily in two ways. First, they aid in preventing tumours from growing new blood vessels, which they require to do so. They target a few of the proteins that cancer cells often produce to aid in their growth. The thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops. The main types of thyroid cancer drugs are radioiodine ablation, thyroid stimulating hormone (THS) suppression, chemotherapy, targeted multikinase therapy, and others. Radioiodine ablation is a type of radiation therapy that uses radioactive iodine to remove or ablate any healthy thyroid tissue that remains following a thyroidectomy. The different types of drugs include ipilimumab, cabozantinib-s-malate, caprelsa (vandetanib), doxorubicin hydrochloride, and lenvatinibmesylate, nivolumab, vandetanib, others and are used in various sectors such as hospitals, oncology clinics, research organizations, others.

What Is The Thyroid Cancer Drugs Market Growth Forecast?

The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to growth in personalized oncology drugs, rising incidence of advanced thyroid cancer, increasing clinical trial activity, expansion of immunotherapy combinations, higher oncology healthcare spending. Major trends in the forecast period include rising adoption of targeted multikinase therapies, increasing use of combination drug regimens, growing focus on advanced and refractory thyroid cancer, expansion of precision oncology treatment approaches, increased hospital-based thyroid cancer management.

What Is The Driver Of The Thyroid Cancer Drugs Market?

Increasing incidences of thyroid cancer are expected to propel the growth of the thyroid cancer drugs market going forward. Thyroid cancer refers to malignant tumors that develop in the thyroid gland and require timely diagnosis and effective therapeutic treatment to prevent disease progression and metastasis. The rise in thyroid cancer is due to a combination of increased detection through more sensitive diagnostic procedures and a increase caused by higher exposure to environmental factors. The increasing incidences of thyroid cancer support the thyroid cancer drugs by boosting demand for targeted therapies, immunotherapies, radiopharmaceuticals, and hormone-suppressing medications that enhance treatment outcomes and long-term survival. For instance, in September 2025, according to Cancer Research United Kingdom, a UK-based non-profit organization focused on cancer research and patient support, around 6,600 new cases of thyroid cancer are projected annually by 2038-2040, with incidence rates expected to rise by 27% from approximately 7.3 cases per 100,000 people per year in 2024-2026 to around 9.2 cases per 100,000. Therefore, increasing incidences of thyroid cancer are driving the growth of the thyroid cancer drugs industry.

Key Players In The Global Thyroid Cancer Drugs Market

Major companies operating in the thyroid cancer drugs market are AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH

Global Thyroid Cancer Drugs Market Trends and Insights

Major companies operating in the thyroid cancer market are innovating products such as selpercatinib to improve treatment options and outcomes for patients. Selpercatinib, marketed as Retevmo is a medication to treat various cancers associated with Rearranged During Transfection (RET) mutations, including advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For instance, in September 2024, Eli Lilly and Company, a US-based pharmaceutical company received approval for selpercatinib (Retevmo) from the Food and Drug Administration (FDA), a US-based federal agency for protecting the public health for the treatment of advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. This approval applies to both adult and pediatric patients aged 2 years and older who require systemic therapy. The recent traditional approval marks a significant advancement in treatment options for patients with this specific type of thyroid cancer.

What Are Latest Mergers And Acquisitions In The Thyroid Cancer Drugs Market?

In October 2024, Sanofi, a France-based pharmaceutical company, partnered with Orano Med, to advance the development of next-generation radioligand therapies for rare cancers, including thyroid cancer. This collaboration aims to combine Sanofi’s drug development capabilities with Orano Med’s expertise in lead-212 (212Pb) alpha-emitting isotope-based radioligand therapies, focusing on discovery, design, and clinical development of novel treatments. Orano Med is a France-based a oncology-focused biotech company pioneer in targeted alpha therapies, specializing in radioligand therapies for rare cancers.

What Defines the Thyroid Cancer Drugs Market?

The thyroid cancer drugs market consists of sales cabozantinib-s-malate, caprelsa, and cometriq. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Thyroid Cancer Drugs Market Report 2026?

The thyroid cancer drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.